NOTTINGHAM, UK – June 4th, 2025 – 4D Medicine Limited, a pioneering developer of advanced biomaterials for orthopaedic and surgical applications, is pleased to announce its participation as an exhibitor at the Orthopaedic Manufacturing & Technology Exposition and Conference (OMTEC) 2025, taking place June 18–19 at the Donald E. Stephens Convention Center in Chicago, Illinois.

Attendees are invited to connect with 4D Medicine at Booth #558, where the company will be showcasing 4Degra®- its innovative bioabsorbable polymer platform that offers unprecedented performance in tissue repair and regeneration. This cutting-edge biomaterial, featuring novel polycarbonate urethane chemistry, is designed to meet the evolving needs of the orthopaedic, spine, and trauma markets. 

4D Medicine will be actively seeking sales channel partners for the Degrafix Interference Screw that delivers improved biocompatibility and more predictable resorption to increase surgeon confidence in long-term procedural success. The DegraFix interference Screw is the first product in a potential portfolio of improved soft tissue fixation devices.

“We are excited to engage with industry leaders and investors at OMTEC 2025,” said Phil Smith, CEO of 4D Medicine Limited. “Our materials offer unique advantages in terms of processibility, biocompatibility, and regenerative potential. We look forward to exploring strategic partnerships that will accelerate commercialization and expand clinical impact.”

Attendees are encouraged to schedule meetings in advance by contacting the 4D Medicine business development team at info@4dmedicine.co.uk.

For more information about 4D Medicine Limited and its novel biomaterial platform, please visit www.4dmedicine.co.uk.

ENDS

NOTTINGHAM, UK. 3rd April, 2025 – 4D Biomaterials Ltd, the materials manufacturing subsidiary of 4D Medicine Ltd, a UK university spin-out company developing next-generation bioresorbable medical devices, today announced it has achieved ISO 13485:2016 certification from The British Standards Institution (BSI). 

This globally recognised quality standard for medical device manufacturing marks a critical milestone in the company’s path to market, demonstrating high quality, low risk and customer-focused manufacturing capability. 

The certification confirms that 4D Biomaterials Ltd operates under a quality management system that meets stringent international regulatory requirements — a core prerequisite for the raw materials used in medical devices seeking regulatory approvals, clinical deployment, and global distribution. As such, certification significantly de-risks the company’s commercial strategy. 

Phil Smith, CEO of parent company, 4D Medicine Ltd commented:

“This achievement is a pivotal moment for our materials manufacturing business. ISO 13485 certification validates its operational systems and sends a clear signal to partners and investors: we are ready to scale. It also reflects the maturity of our technology platform, the discipline of our team, and our commitment to executing a high-quality commercialisation strategy.”

This milestone positions 4D to accelerate the development of commercial partnerships, regulatory approvals, and revenue-generating opportunities as it advances its differentiated product pipeline toward global markets.

ENDS

NOTTINGHAM, UK. March 11th, 2025 – 4D Medicine Ltd, an emerging innovator in the biomaterials and medical device sector, is proud to announce the launch of its newly redesigned corporate website, www.4dmedicine.co.uk.

The site is designed to offer a comprehensive resource for investors, strategic partners, and healthcare professionals, highlighting the company’s groundbreaking 4Degra® bioabsorbable polymer technology and its potential to transform the medical device industry.

The new website offers information on the unique properties of 4Degra®, a next-generation bioabsorbable polymer developed to improve patient outcomes in medical device applications. 4Degra®’s unparalleled versatility and biocompatibility make it an ideal material for a wide range of devices, including those used in musculoskeletal repair, soft tissue regeneration and drug-delivery.

“4Degra® represents the next evolution in bioabsorbable materials, and this website serves as an essential tool to communicate the exciting opportunities that lie ahead for investors and collaborators,” said Phil Smith, CEO of 4D Medicine. 

“We’ve designed the site to not only inform but to also demonstrate the potential impact our technology can have in improving surgical outcomes and improving lives.”

Key features of the new website include:

The launch of this website underscores 4D Medicine’s commitment to transparency, collaboration, and ongoing innovation. The company is poised to lead the way in delivering solutions that enhance patient care and create lasting value for its partners and stakeholders.

ENDS